迪瑞医疗(300396) - 2024 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2024 was ¥297,174,611.23, a decrease of 15.97% year-over-year, while year-to-date revenue reached ¥1,175,445,053.92, an increase of 12.10%[2] - Net profit attributable to shareholders for Q3 2024 was ¥27,334,486.91, down 62.28% year-over-year, with year-to-date net profit at ¥192,577,440.82, a decrease of 17.80%[2] - Basic and diluted earnings per share for Q3 2024 were both ¥0.1002, reflecting a decline of 62.47% compared to the same period last year[2] - The net profit for Q3 2024 was approximately ¥192.57 million, a decrease of 17.7% compared to ¥234.27 million in Q3 2023[17] - The total operating profit was ¥214.11 million, down 16.5% from ¥256.42 million in Q3 2023[17] - The company reported a total comprehensive income of ¥193.43 million, a decrease of 16.6% from ¥231.88 million in the previous year[18] Assets and Liabilities - The company's total assets as of the end of Q3 2024 were ¥3,070,950,229.04, a decrease of 7.52% from the end of the previous year[2] - Total assets decreased to ¥3,070,950,229.04 from ¥3,320,764,441.14, a reduction of 7.5%[15] - Total liabilities decreased to ¥974,554,696.64 from ¥1,281,453,034.50, a decline of 23.9%[15] - The equity attributable to shareholders increased to ¥2,096,375,860.39, up from ¥2,039,281,003.59, a growth of 2.8%[15] Cash Flow - Cash flow from operating activities showed a net outflow of ¥299,371,952.53, representing a significant decline of 637.22% year-over-year[2] - The net cash flow from operating activities was negative at ¥299.37 million, compared to a positive cash flow of ¥55.73 million in Q3 2023[19] - The company’s investment activities generated a net cash inflow of ¥7.52 million, a significant decrease from ¥61.08 million in the previous year[20] - The company reported a net investment income of ¥20,686,292.54, down from ¥26,911,000.18, a decrease of 23.1%[16] Accounts Receivable and Inventory - The company reported a 36.78% increase in accounts receivable compared to the beginning of the period, amounting to an increase of ¥158,953,600[5] - Accounts receivable increased to ¥591,080,039.40, up 36.8% from ¥432,126,395.59 at the beginning of the period[13] - Inventory decreased to ¥492,717,834.54, down 13.9% from ¥572,935,454.69[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,095[8] - The largest shareholder, Shenzhen Huadexin Run Equity Investment Enterprise, holds 28.34% of shares, totaling 77,288,400 shares[8] - Guangdong Hengjian International Investment Co., Ltd. holds 12.15% of shares, totaling 33,123,600 shares[8] - The number of shares held by the top ten shareholders includes significant stakes from individual shareholders, such as Song Jie with 6.32%[8] - The company has not disclosed any related party relationships among the top shareholders[9] Stock Repurchase and Capital Changes - The company repurchased and canceled 132,547 restricted stocks due to unmet conditions for the first release period of the 2022 restricted stock incentive plan[11] - A total of 1,865,750 restricted stocks were repurchased and canceled due to unmet conditions for the 2021 and 2022 restricted stock incentive plans[12] - The company's total share capital has changed to 274,565,911 shares after the cancellation of restricted stocks[11] - The company’s registered capital has changed to 272,700,161 yuan after the cancellation of restricted stocks[12] - The total number of restricted shares at the beginning of the period was 19,562,663, with 17,345,325 released during the period[10] Expenses - Total operating costs amounted to ¥986,818,603.55, up 18.3% from ¥834,307,086.89 year-over-year[16] - Research and development expenses were ¥95,643,187.59, reflecting an increase of 12.5% compared to ¥85,343,396.06 in the previous year[16] - Management expenses decreased by ¥17,268,200, down 33.49% year-over-year, due to cost control measures and optimization of functional systems[6] Credit and Impairment - The company experienced a 400.20% increase in credit impairment losses, amounting to an increase of ¥9,508,100, due to an increase in accounts receivable and higher bad debt provisions[6] Cash and Equivalents - The company's cash and cash equivalents decreased to ¥471,019,852.83 from ¥845,730,745.23, a decline of 44.4%[13] - The cash and cash equivalents at the end of the period were ¥459.57 million, a decrease from ¥756.52 million at the end of Q3 2023[20] Foreign Exchange - The company recorded a foreign exchange gain of ¥867,496.48, compared to a loss of ¥2.38 million in the same quarter last year[18]